Flavonoids as Cytokine Modulators: A Possible Therapy for Inflammation-Related Diseases

被引:239
作者
Leyva-Lopez, Nayely [1 ]
Gutierrez-Grijalva, Erick P. [1 ]
Ambriz-Perez, Dulce L. [2 ]
Basilio Heredia, J. [1 ]
机构
[1] Ctr Invest Alimentac & Desarrollo AC, Carretera Eldorado Km 5-5 Col El Diez, Culiacan 80110, Sinaloa, Mexico
[2] Univ Politecn Mar & Sierra, Carretera Potrerillos Norote La Cruz Km 3, Elota 82740, Sinaloa, Mexico
关键词
flavonoids; anti-inflammatory effect; cytokine inhibition; NF-KAPPA-B; LIPOPOLYSACCHARIDE (LPS)-INDUCED INFLAMMATION; AMYLOID BETA-PEPTIDE; RHEUMATOID-ARTHRITIS; PROTECTIVE ROLE; ANTIINFLAMMATORY ACTIVITY; INTERLEUKIN-6; RECEPTOR; AUTOIMMUNE-DISEASES; SIGNALING PATHWAY; PLANT FLAVONOIDS;
D O I
10.3390/ijms17060921
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
High levels of cytokines, such as interleukin (IL)-1 beta, tumor necrosis factor (TNF)-alpha and IL-6, are associated with chronic diseases like rheumatoid arthritis, asthma, atherosclerosis, Alzheimer's disease and cancer; therefore cytokine inhibition might be an important target for the treatment of these diseases. Most drugs used to alleviate some inflammation-related symptoms act by inhibiting cyclooxygenases activity or by blocking cytokine receptors. Nevertheless, these drugs have secondary effects when used on a long-term basis. It has been mentioned that flavonoids, namely quercetin, apigenin and luteolin, reduce cytokine expression and secretion. In this regard, flavonoids may have therapeutical potential in the treatment of inflammation-related diseases as cytokine modulators. This review is focused on current research about the effect of flavonoids on cytokine modulation and the description of the way these compounds exert their effect.
引用
收藏
页数:15
相关论文
共 113 条
[11]  
BLAY JY, 1992, CANCER RES, V52, P3317
[12]   The role of cytokines in the pathogenesis of rheumatoid arthritis - Practical and potential application of cytokines as biomarkers and targets of personalized therapy [J].
Brzustewicz, Edyta ;
Bryl, Ewa .
CYTOKINE, 2015, 76 (02) :527-536
[13]   Luteolin suppresses IL-1β-induced cytokines and MMPs production via p38 MAPK, JNK, NF-kappaB and AP-1 activation in human synovial sarcoma cell line, SW982 [J].
Choi, Eun Mi ;
Lee, Young Soon .
FOOD AND CHEMICAL TOXICOLOGY, 2010, 48 (10) :2607-2611
[14]  
Chow CW, 2006, CLIN CRITICAL CARE M, V1, P1
[15]   Molecular inflammation: Underpinnings of aging and age-related diseases [J].
Chung, Hae Young ;
Cesari, Matteo ;
Anton, Stephen ;
Marzetti, Emanuele ;
Giovannini, Silvia ;
Seo, Arnold Young ;
Carter, Christy ;
Yu, Byung Pal ;
Leeuwenburgh, Christiaan .
AGEING RESEARCH REVIEWS, 2009, 8 (01) :18-30
[16]   Inhibition of pro-inflammatory markers in primary bone marrow-derived mouse macrophages by naturally occurring flavonoids:: Analysis of the structure-activity relationship [J].
Comalada, Monica ;
Ballester, Isabel ;
Bailon, Elvira ;
Xaus, Jordi ;
Galvez, Julio ;
Sanchez de Medina, Fermin ;
Zarzuelo, Antonio .
BIOCHEMICAL PHARMACOLOGY, 2006, 72 (08) :1010-1021
[17]   Expression of the interleukin 6 receptor in primary renal cell carcinoma [J].
Costes, V ;
Liautard, J ;
Picot, MC ;
Robert, M ;
Lequeux, N ;
Brochier, J ;
Baldet, P ;
Rossi, JF .
JOURNAL OF CLINICAL PATHOLOGY, 1997, 50 (10) :835-840
[18]   Etanercept - A review of its use in the management of rheumatoid arthritis [J].
Dhillon, Sohita ;
Lyseng-Williamson, Katherine A. ;
Scott, Lesley J. .
DRUGS, 2007, 67 (08) :1211-1241
[19]   Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study [J].
Egert, Sarah ;
Bosy-Westphal, Anja ;
Seiberl, Jasmin ;
Kuerbitz, Claudia ;
Settler, Uta ;
Plachta-Danielzik, Sandra ;
Wagner, Anika E. ;
Frank, Jan ;
Schrezenmeir, Juergen ;
Rimbach, Gerald ;
Wolffram, Siegfried ;
Mueller, Manfred J. .
BRITISH JOURNAL OF NUTRITION, 2009, 102 (07) :1065-1074
[20]   IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [J].
Emery, P. ;
Keystone, E. ;
Tony, H. P. ;
Cantagrel, A. ;
van Vollenhoven, R. ;
Sanchez, A. ;
Alecock, E. ;
Lee, J. ;
Kremer, J. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1516-1523